BDTXHealthcare · BiotechnologyThe 8 Wall Street analysts covering Black Diamond Therapeutics, Inc. hold a median 12-month price target of $10 — +407.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Black Diamond Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (81): The business earns solid, repeatable profits on what it owns.
Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BDTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +407.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | BTIG | Maintains | Buy | $10 → $11 |
| 17 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 16 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Dec 2025 | Guggenheim | Downgrade | Neutral | — |
| 18 Nov 2025 | Piper Sandler | Assumes | Overweight | $9.00 |
| 16 Oct 2025 | Stifel | Reinstates | Buy | $8.00 |
| 1 Oct 2025 | Freedom Broker | Initiates | Buy | — |
| 4 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | Raymond James | Reinstates | Outperform | $11 |
| 18 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | Stifel | Maintains | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Oct 2024 | Wedbush | Reiterates | Outperform | — |
| 24 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Sept 2024 | Piper Sandler | Maintains | Overweight | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Sept 2024 | Wedbush | Reiterates | Outperform | — |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Black Diamond Therapeutics, Inc. returned −41.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 63% of US stocks
Cheaper than 58% of US stocks
Cheaper than 68% of US stocks
Cheaper than 64% of US stocks
Higher than 1% of US stocks
Higher than 86% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Black Diamond Therapeutics, Inc. has a market value of $112.9M and an enterprise value of $20.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$42.6M.
Diluted earnings per share, trailing twelve months: $−0.75.
Free cash flow in the twelve months to 30 June 2026: −$32.8M.
Trailing P/E: 7.2×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Black Diamond Therapeutics, Inc. employs 21 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Black Diamond Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Black Diamond (BDTX) reported earnings 30 days ago, and its stock has risen 9.4% since that report. The article examines what could happen next for the stock following this gain.
Why it matters — BDTX watchers would care because the piece assesses the stock's momentum since its last earnings report and considers its near-term outlook.
Black Diamond Therapeutics announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 2, 2026, via GlobeNewsWire.
Why it matters — The company's participation in a major investment conference provides BDTX watchers with an opportunity to hear directly from its Chief Scientific Officer about its clinical-stage oncology programs.
Black Diamond Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The clinical-stage oncology company, which is developing MasterKey therapies including the EGFR inhibitor silevertinib, announced the results on August 5, 2026.
Why it matters — BDTX watchers would want to track the company's latest financial results and corporate update for signs of progress on its oncology pipeline, including silevertinib.
The 8 Wall Street analysts covering Black Diamond Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Black Diamond Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Black Diamond Therapeutics, Inc. 57 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Black Diamond Therapeutics, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (81 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +407.6% from the last close, and Ticker Nerd's factor model ranks Black Diamond Therapeutics, Inc. 57 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Black Diamond Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
Black Diamond Therapeutics, Inc. returned -41.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?". Black Diamond (BDTX) reported earnings 30 days ago, and its stock has risen 9.4% since that report. The article examines what could happen next for the stock following this gain.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers. The company’s current programs center on small-molecule MasterKey therapies designed to target families of oncogenic mutations across multiple tumor types, with an emphasis on overcoming resistance and addressing tumors that are difficult to treat with standard approaches. Its lead clinical asset, silevertinib, is a brain-penetrant EGFR inhibitor being studied in non-small cell lung cancer and glioblastoma. Black Diamond Therapeutics also advances additional oncology candidates in its pipeline aimed at other mutation-driven solid tumors. Based in Cambridge, Massachusetts, the company plays a role in the biotechnology market as a developer of targeted cancer therapies intended for patients whose tumors are driven by specific genetic alterations.
CEO Dr. Mark A. Velleca M.D., Ph.D. · 21 employees · United States · https://www.blackdiamondtherapeutics.com
